

# LUPIN LIMITED

## SAFETY DATA SHEET

### Section 1: Identification

#### Section 1, Identification

<b>Material</b>	<b>WYMZYA™ Fe</b> <b>[Norethindrone and Ethinyl Estradiol Tablets USP (chewable), 0.4 mg/0.035 mg and Ferrous Fumarate Tablets, 75 mg]</b>
<b>Manufacturer</b>	<b>Lupin Limited</b> Pithampur (M.P.) – 454 775 INDIA.
<b>Distributor</b>	Lupin Pharmaceuticals, Inc. 111 South Calvert Street, Harborplace Tower, 21st Floor, Baltimore, Maryland 21202 United States Tel. 001-410-576-2000 Fax. 001-410-576-2221

### Section 2: Hazard(s) Identification

#### Section 2, Hazard(s) identification

<b>Fire and Explosion</b>	Expected to be non-combustible.
<b>Health</b>	<p>Do not prescribe WYMZYA Fe to women who are known to have the following conditions:</p> <ul style="list-style-type: none"><li>• A high risk of arterial or venous thrombotic diseases. Examples include women who are known to:<ul style="list-style-type: none"><li>○ Smoke, if over age 35</li><li>○ Have deep vein thrombosis or pulmonary embolism, now or in the past</li><li>○ Have inherited or acquired hypercoagulopathies</li><li>○ Have cerebrovascular disease</li><li>○ Have coronary artery disease</li><li>○ Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)</li><li>○ Have uncontrolled hypertension</li><li>○ Have diabetes mellitus with vascular disease</li><li>○ Have headaches with focal neurological symptoms or have migraine headaches with aura<ul style="list-style-type: none"><li>▪ Women over age 35 with any migraine headaches</li></ul></li></ul></li><li>• Liver tumors, benign or malignant, or liver disease</li><li>• Undiagnosed abnormal uterine bleeding</li><li>• Pregnancy, because there is no reason to use COCs during pregnancy</li><li>• Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past</li><li>• Hypersensitivity to any of the components.</li><li>• Use of Hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for ALT elevations</li></ul>

**Environment**

No information is available about the potential of this product to produce adverse environmental effects.

## Section 3: Composition/Information on Ingredients

**Section 3, Composition/information on ingredients**

<b>Ingredients</b>	<b>CAS</b>
Norethindrone USP	68-22-4
Ethinyl Estradiol USP	57-63-6

## Section 4: First-Aid Measures

**Section 4, First-aid measures**

<b>Ingestion</b>	If accidental ingestion occurs, flush mouth out with water and get medical attention.
<b>Inhalation</b>	The risk of inhalation exposure is negligible when product is in its final packaged form. If exposed and become symptomatic, move to fresh air and get medical attention.
<b>Skin Contact</b>	Wash off immediately with plenty of water. Continue to rinse for at least 15 minutes. Get medical attention if irritation develops and persists.
<b>Eye Contact</b>	In case of eye contact, remove contact lens and rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes. Get medical attention.

**NOTES TO HEALTH PROFESSIONALS**

<b>Medical Treatment</b>	Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information center. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.
<b>OVERDOSAGE</b>	There have been no reports of serious ill effects from overdosage of oral contraceptives, including ingestion by children. Overdosage may cause withdrawal bleeding in females and nausea.

## Section 5: Fire-Fighting Measures

**Section 5, Fire-fighting measures**

<b>Fire and Explosion Hazards</b>	Assume that this product is capable of sustaining combustion.
<b>Extinguishing Media</b>	Water spray, carbon dioxide, dry chemical powder or appropriate foam.
<b>Special Firefighting Procedures</b>	For single units (packages): No special requirements needed. For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapors might be evolved from fires involving this product and associated packaging, self-contained breathing apparatus and full protective equipment are recommended for firefighters.
<b>Hazardous Combustion Products</b>	Hazardous combustion or decomposition products are expected when the product is exposed to fire.

## Section 6: Accidental Release Measures

### Section 6, Accidental release measures

<b>Personal Precautions</b>	Wear suitable protective clothing, gloves and eye/face protection.
<b>Environmental Precautions</b>	Avoid release to the environment.
<b>Clean-up Methods</b>	Collect and place it in a suitable, properly labeled container for recovery or disposal.

## Section 7: Handling and Storage

### Section 7, Handling and storage

<b>Handling</b>	No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.
<b>Storage</b>	Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature]. Keep this and all medications out of the reach of children.

## Section 8: Exposure Controls/Personal Protection

### Section 8, Exposure controls/personal protection

Wear appropriate clothing to avoid skin contact. Wash hands and arms thoroughly after handling.

## Section 9: Physical and Chemical Properties

### Section 9, Physical and chemical properties

<b>Physical Form</b>	<b>How Supplied</b>
	WYMZYA Fe [norethindrone and ethinyl estradiol tablets USP (chewable) and ferrous fumarate tablets] is available in a blister pack (NDC 68180-873-71) containing 28 tablets packed in a pouch (NDC 68180-873-71). Such three pouches are packaged in a carton (NDC 68180-873-73).
	Each blister contains 28 tablets in the following order: <ul style="list-style-type: none"><li>• 21 white to off-white, round (active), flat face, beveled edge tablets debossed with "LU" on one side and "M21" on the other side and each containing 0.4 mg norethindrone and 35 mcg ethinyl estradiol.</li><li>• 7 brown, mottled, round (non-hormonal placebo), flat face, beveled edge tablets debossed with "LU" on one side and "M22" on the other side and each containing 75 mg ferrous fumarate.</li></ul>

## Section 10: Stability and Reactivity

### Section 10, Stability and reactivity

The product is stable and non-reactive under normal conditions of use, storage and transport.

## Section 11: Toxicological Information

### Section 11, Toxicological information

#### Carcinoma of the Breast and Cervix

WYMZYA Fe is contraindicated in women who currently have or have had breast cancer because breast cancer may be hormonally sensitive.

There is substantial evidence that COCs do not increase the incidence of breast cancer. Although some past studies have suggested that COCs might increase the incidence of breast cancer, more recent studies have not confirmed such findings.

Some studies suggest that COC use has been associated with an increase in the risk of cervical cancer or intraepithelial neoplasia. However, there continues to be controversy about the extent to which such findings may be due to differences in sexual behavior and other factors.

## Section 12: Ecological Information

### Section 12: Ecological Information

No relevant studies identified.

## Section 13: Disposal Considerations

### Section 13: Disposal Considerations

Incinerate in an approved facility. Follow all federal state and local environmental regulations.

## Section 14: Transport Information

### Section 14: Transport Information

#### IATA/ICAO - Not Regulated

IATA Proper shipping Name	:	N/A
IATA UN/ID No	:	N/A
IATA Hazard Class	:	N/A
IATA Packaging Group	:	N/A
IATA Label	:	N/A

#### IMDG - Not Regulated

IMDG Proper shipping Name	:	N/A
IMDG UN/ID No	:	N/A
IMDG Hazard Class	:	N/A
IMDG Flash Point	:	N/A
IMDG Label	:	N/A

#### DOT - Not Regulated

DOT Proper shipping Name	:	N/A
DOT UN/ID No	:	N/A
DOT Hazard Class	:	N/A
DOT Flash Point	:	N/A
DOT Packing Group	:	N/A
DOT Label	:	N/A

## Section 15: Regulatory Information

### Section 15: Regulatory Information

This Section Contains Information relevant to compliance with other Federal and/or state laws.

## Section 16: Other Information

### Section 16, Other information

The above information is believed to be correct but does not purport to be all-inclusive and shall be used only as a guide. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

**Lupin** shall not be held liable for any damage resulting from handling or from contact with the above product. Lupin reserves the right to revise this SDS.